Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Per 012009
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(664)
•••
Comment by DeathXray33on Oct 28, 2024 9:25am
146 Views
Post# 36284725

RE:RE:RE:RE:Per 012009

RE:RE:RE:RE:Per 012009
CancerSlayer wrote:
Longholder99 wrote:  I wonder if the specified lack of side effects and/or quality of life reporting that we arent seeing in the clinical reports could be coming via the extra steps taken by the central lab (reaching out to patients once again) as a way of seeking verification of the surrogate endpoints required for AA approval?  


It is my understanding that the FDA guidelines indicate that a single-arm trial that demonstrates a competitive CR rate (primary endpoint) & that rate is supported by a durable response provides sufficient evidence of efficacy to support a marketing application/AA.  Any of the other secondary endpoints such as QOL, event/progressiom-free survival, cost, etc. (though important data sets for confirmatory studies) do not influence AA eligibility.  All imo...good luck.


Moderna: "The stock has dropped 46% so far this year and 56% in the past three months" Merck: down 19% in three months.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities